Vital Therapies (VTL) Stock Rating Lowered by ValuEngine

ValuEngine cut shares of Vital Therapies (NASDAQ:VTL) from a buy rating to a hold rating in a research report report published on Wednesday.

VTL has been the topic of several other reports. Cantor Fitzgerald started coverage on shares of Vital Therapies in a report on Monday, August 20th. They set an overweight rating and a $18.00 target price on the stock. BidaskClub upgraded shares of Vital Therapies from a hold rating to a buy rating in a report on Saturday, June 30th. BTIG Research restated a hold rating on shares of Vital Therapies in a report on Monday, May 28th. Finally, William Blair restated a buy rating on shares of Vital Therapies in a report on Sunday, August 12th. Seven equities research analysts have rated the stock with a hold rating, Vital Therapies presently has an average rating of Hold and a consensus price target of $12.00.

Shares of Vital Therapies stock opened at $0.35 on Wednesday. Vital Therapies has a 1 year low of $0.33 and a 1 year high of $9.75.

Vital Therapies (NASDAQ:VTL) last issued its earnings results on Tuesday, August 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.33) by $0.03. equities analysts forecast that Vital Therapies will post -1.19 earnings per share for the current year.

Large investors have recently added to or reduced their stakes in the company. Citigroup Inc. raised its position in shares of Vital Therapies by 1,093.5% in the 1st quarter. Citigroup Inc. now owns 15,909 shares of the company’s stock valued at $108,000 after purchasing an additional 14,576 shares during the last quarter. Quantitative Systematic Strategies LLC purchased a new position in shares of Vital Therapies in the 2nd quarter valued at approximately $139,000. Rhumbline Advisers purchased a new position in shares of Vital Therapies in the 2nd quarter valued at approximately $183,000. Element Capital Management LLC purchased a new position in shares of Vital Therapies in the 1st quarter valued at approximately $209,000. Finally, TD Asset Management Inc. raised its position in shares of Vital Therapies by 50.2% in the 2nd quarter. TD Asset Management Inc. now owns 36,344 shares of the company’s stock valued at $249,000 after purchasing an additional 12,144 shares during the last quarter. Institutional investors and hedge funds own 32.62% of the company’s stock.

Vital Therapies Company Profile

Vital Therapies, Inc, a biotherapeutic company, focuses on developing and commercializing a cell-based therapy for the treatment of acute forms of liver failure in the United States. Its product candidate is the ELAD system, an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials helps in enhancing the rates of survival in patients with acute forms of liver failure.

Featured Article: What is a Fiduciary?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply